Home・Список акций・Moderna Inc

Moderna Inc

Закрыт

СекторЗдравоохранение

56.94 3.32

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

55.11

Макс.

58.19

Ключевые показатели
By Trading Economics
Доход	561M -782M
Продажи	-244M 145M
Прибыль на акцию	-1.97
Рентабельность продаж	-539.31
Сотрудники	4,700
EBITDA	554M -704M

Рекомендации
By TipRanks
Рекомендации	Нейтрально
Прогноз на 12 месяцев	-11.28% downside

Дивиденды
By Acuity
Следующий отчет о доходах	5 нояб. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-194M 22B
Предыдущая цена открытия	53.62
Предыдущая цена закрытия	56.94

Новостные настроения

By Acuity

29%

71%

110 / 340 Рейтинг в Healthcare

Moderna Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

4 авг. 2026 г., 20:07 UTC

Social Media

News

Moderna initiates Phase 1 trial for mRNA-1469 vaccine, backed by CEPI's $50 million funding. Shares are higher despite earlier session pullback.

3 авг. 2026 г., 20:03 UTC

News

Moderna Inc. shares are advancing as Citigroup raises its price target to $60 amid broader market strength and gains in major tech stocks.

31 июл. 2026 г., 23:26 UTC

Moderna Inc. shares are lower in after-hours trading, continuing a decline from Friday's close without any specific news to explain the movement.

30 июл. 2026 г., 23:51 UTC

Moderna Inc shares are higher in after-market trading, driven by a significant advance in the overall market, despite earlier fluctuations during the session.

29 июл. 2026 г., 23:51 UTC

Moderna Inc is rising in after-market trading, aligning with broader market gains. The stock showed volatility earlier in the session without specific news driving the move.

28 июл. 2026 г., 18:36 UTC

Moderna Inc shares are lower today, continuing a decline from Monday's close amid risk-off sentiment following significant declines in Asian markets.

27 июл. 2026 г., 19:07 UTC

Social Media

Moderna Inc. is advancing as it initiates a Phase 1 trial for its mRNA-4200 cancer vaccine, with the first U.S. participant dosed on July 16, 2026.

24 июл. 2026 г., 19:03 UTC

Social Media

News

Moderna Inc shares are lower today amid mixed options sentiment and increased demand for downside protection ahead of its upcoming earnings report.

23 июл. 2026 г., 19:56 UTC

Social Media

News

Moderna Inc shares are lower, trading around $57.25, as options activity remains light. An mRNA vaccine is set for a Phase 1 trial in August.

21 июл. 2026 г., 20:07 UTC

News

Social Media

Goldman Sachs raised Moderna's price target to $49.00 while maintaining a Neutral rating, reflecting a more favorable outlook on the company's valuation. Shares are higher today.

20 июл. 2026 г., 23:46 UTC

Moderna Inc shares are lower in after-market hours amid rising Treasury yields and broader market trends, with no specific company news identified.

Сравнение c конкурентами

Изменение цены

Moderna Inc Прогноз

Целевая цена

By TipRanks

-11.28% падение

Прогноз на 12 месяцев

Средняя 48.92 USD -11.28%

Максимум 77 USD

Минимум 39 USD

Основано на мнении 15 аналитиков Wall Street, спрогнозировавших целевые цены для Moderna Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

15 ratings

Покупка

Удержание

Продажа

Основано на мнении 15 аналитиков, присваивавших рейтинги акциям Moderna Inc – Данные за последние 3 месяца.

Настроения

By Acuity

110 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Moderna Inc

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.